Experts briefly mention other ongoing phase 3 studies investigating TAR-200 for the treatment of non–muscle-invasive bladder cancer (NMIBC).

Video content above is prompted by the following: The eligibility criteria of the PEACE-3 trial are different from the patient demographics we see here in the US; how would you go about applying the ...

Experts discuss the patient demographics and clinical trial design of the phase 2b SunRISe-1 study investigating the use of TAR-200 as a monotherapy and in combination with cetrelimab (a PD-1 ...

Panelists discuss how regulatory approval of the radium-223 and enzalutamide combination would likely lead to significant guideline updates, particularly in treatment sequencing recommendations for ...

The mean absorbed radiation dose to tumors was 8.9 Gy/GBq, compared with 0.27 Gy/GBq in the kidneys and 0.13 Gy/GBq in the salivary glands.

“The main challenge at the moment is patients are being diagnosed with metastatic disease far earlier than they would have been otherwise, and therefore [are being] considered for combination systemic ...

"The relaxation of the restrictions that started during COVID are critically important for continued access," says Mark T. Edney, MD. Many of the telehealth flexibilities that were implemented during ...

“For someone that might be looking at getting into sacral neuromodulation, and has had some reluctance in the past, this does simplify the procedure somewhat," says Colin Goudelocke, MD. Six-month ...

"A 14-month delay in disease progression is a very meaningful end point to our patients, because that basically means delay in symptoms, delay in fractures, [and] delay in pain in the ...

"The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD. The final patient visit has been ...

"I'm so excited about them finally removing this boxed warning," says Helen L. Bernie, DO, MPH. The FDA’s recent announcement of class-wide labeling changes for testosterone products was met with ...

The goal of the trial is to improve quality of life by identifying patients who can safely reduce or avoid treatment with hormone therapy. The first patient has been enrolled in the phase 3 ...